文献速递胸部肿瘤放疗放疗物理与技术

美国镭学会适用标准:不可同步化疗的局部晚期NSCLC多学科管理中的加速大分割放疗

American Radium Society Appropriate Use Criteria: Accelerated hypofractionated radiotherapy in the multidisciplinary management of locally-advanced non-small cell lung cancer ineligible for concurrent chemotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-10-13

美国镭学会胸部适用标准专家组针对不可同步化疗的局部晚期非小细胞肺癌(NSCLC),通过 modified Delphi 法评估加速大分割放疗在多学科管理中的适用性。文献回顾纳入14项前瞻性试验/登记研究,达成共识:IMRT和质子治疗适用,肺V20Gy<30%、心脏V40Gy<20%;15次加速大分割时邻近食管或臂丛区域剂量不超过45-55 Gy;巩固免疫治疗适用而同步免疫治疗不适用;常规分割60 Gy/30次仍适用。

要点

  • IMRT和质子治疗适用于局部晚期NSCLC的加速大分割放疗,目标肺V20Gy<30%、心脏V40Gy<20%。
  • 15次加速大分割用于邻近食管或臂丛病变时,剂量超过45-55 Gy不适用。
  • 巩固性PD-L1免疫治疗适用,同步免疫治疗不适用;常规分割60 Gy/30次仍适用。

核心结论

  • 在缺乏证明加速大分割优效性的随机前瞻性数据情况下,常规分割放疗至60 Gy/30次仍是不可同步化疗局部晚期NSCLC的适用选择。
  • 专家组共识认为IMRT和质子治疗适用于局部晚期NSCLC各表现类型的加速大分割放疗,以约束肺V20Gy<30%和心脏V40Gy<20%。

研究设计与样本

  • 由15名成员组成的美国镭学会胸部适用标准多学科专家组制定5个代表局部晚期NSCLC表现的临床变异病例。
  • 正式回顾2010-2025年英文医学文献,聚焦不可同步化疗患者使用加速大分割的前瞻性临床试验,采用改良Delphi法评估所有病例变异。
  • 共识推荐经美国镭学会执行委员会审查批准并接受公众评论。

主要发现

  • 文献回顾识别228篇文章,其中14项前瞻性试验/登记研究,包括9项I-II期试验、4项前瞻性登记和1项随机III期试验。

关键数值与推荐

  • 专家组共识:使用加速大分割时,肺V20Gy<30%和心脏V40Gy<20%是约束目标。
  • 专家组共识:15次加速大分割用于邻近食管或臂丛的病变时,超过45-55 Gy的剂量不适用。
  • 专家组共识:根治性放疗后巩固性PD-L1免疫治疗适用,同步免疫治疗不适用。
  • 专家组共识:对于大块或N3病变,放疗前诱导PD-L1免疫治疗以测试疾病生物学可能适用。
  • 专家组共识:常规分割放疗至60 Gy/30次在各变异中仍适用。

临床怎么用

  • 对不可同步化疗的局部晚期NSCLC,可选用加速大分割放疗并采用IMRT或质子治疗,同时约束肺V20Gy<30%和心脏V40Gy<20%。
  • 15次加速大分割用于邻近食管或臂丛病变时,应避免超过45-55 Gy的剂量。
  • 放疗后可行巩固性PD-L1免疫治疗,但不应同步进行免疫治疗;大块或N3病变可考虑放疗前诱导免疫治疗以测试生物学。
  • 常规分割60 Gy/30次仍是适用选项,尤其在缺乏加速大分割优效性随机证据时。

局限性

  • 加速大分割放疗缺乏随机前瞻性证据指导应用,文献中仅1项随机III期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While accelerated hypofractionated radiotherapy has increasingly been adopted in the multidisciplinary management of locally-advanced non-small cell lung cancer (NSCLC) ineligible for concurrent chemotherapy, there is a paucity of randomized prospective evidence guiding utilization. Given the marked heterogeneity in the presentations of locally-advanced NSCLC, the American Radium Society (ARS) Thoracic Appropriate Use Criteria (AUC) Panel evaluated the appropriateness of accelerated hypofractionation in the context of multidisciplinary management. METHODS: Five clinical variants representing manifestations of locally-advanced NSCLC were developed by the 15-member multidisciplinary ARS Thoracic AUC panel. The English-language medical literature was formally reviewed from 2010-2025 and scrutinized for prospective clinical trials utilizing accelerated hypofractionation for concurrent chemotherapy ineligible patients. All case variants were evaluated with respect to use of radiation technique, radiation fractionation, and utilization of programmed death-ligand 1 (PD-L1) immunotherapy with Modified Delphi methodology. Consensus recommendations were reviewed and approved by the ARS Executive Committee and subject to public comment. RESULTS: The literature review identified 228 articles, of which there were 14 prospective trials/registries including nine Phase I-II trials, four prospective registries, and one randomized Phase III trial. There was consensus that it is appropriate to utilize intensity modulated radiation therapy and proton therapy across presentations of locally-advanced NSCLC, with the aim of constraining the lung V20Gy<30% and heart V40Gy<20% with accelerated hypofractionation. When utilizing 15-fraction accelerated hypofractionation for disease abutting the esophagus or brachial plexus, there was consensus that it is inappropriate to exceed doses of 45-55 Gy. With respect to PD-L1 immunotherapy, there was consensus that consolidative immunotherapy after definitive radiation therapy is appropriate, but that concurrent immunotherapy is inappropriate. There was panel consensus that it may be appropriate to utilize induction PD-L1 immunotherapy prior to radiation therapy in cases of bulky or N3 disease to test disease biology. Across variants, there was consensus that conventionally fractionated radiotherapy to 60 Gy in 30 fractions remains appropriate. CONCLUSIONS: The ARS Thoracic AUC Panel has provided consensus case-based guidelines on the multidisciplinary management of locally-advanced NSCLC ineligible for concurrent chemotherapy reflecting the heterogeneity of disease presentation in this population. In absence of randomized prospective data demonstrating superiority of accelerated hypofractionation, conventionally fractionated radiotherapy remains an appropriate option.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chun SG, Iyengar P, Rimner A, et al. American Radium Society Appropriate Use Criteria: Accelerated hypofractionated radiotherapy in the multidisciplinary management of locally-advanced non-small cell lung cancer ineligible for concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 42869299. doi:10.1016/j.ijrobp.2026.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。